公开(公告)号：US20190100724A1

公开(公告)日：2019-04-04

申请号：US16082837

申请日：2017-02-17

Applicant: KEIO UNIVERSITY ,  OSAKA UNIVERSITY

Inventor： Toshiro SATO ,  Mami MATANO ,  Shinya SUGIMOTO ,  Junichi TAKAGI

IPC: C12N5/00 ,  C12N5/095 ,  C12N5/071

Abstract: The present invention provides a cell culture medium with which serum-free long-term culture of an epithelial stem cell, an epithelial cancer cell, or a tissue containing at least one thereof can be achieved. The cell culture medium of the present invention includes: a Wnt agonist composed of a complex of Wnt protein and afamin, which is a substance capable of stabilizing the Wnt protein, and R-spondin; and at least one selected from the group consisting of a mitogenic growth factor, a bone morphogenetic protein (BMP) inhibitor, a transforming growth factor-β (TGF-β) inhibitor, and a p38 inhibitor.

公开(公告)号：US20240360222A1

公开(公告)日：2024-10-31

申请号：US18662493

申请日：2024-05-13

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09

CPC classification number: C07K16/2839 ,  A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20190390160A1

公开(公告)日：2019-12-26

申请号：US16565898

申请日：2019-09-10

Applicant: OSAKA UNIVERSITY

Inventor： Junichi TAKAGI ,  Emiko MIHARA ,  Akira KIKUCHI

IPC: C12N5/00 ,  C12N15/09 ,  C12P21/02 ,  C07K19/00 ,  A61K38/00

Abstract: Provided is a novel method for producing a Wnt protein, which method comprises (1) a step of performing affinity purification targeting afamin to obtain a Wnt protein from a culture product, and/or (2) a step of performing affinity purification to obtain a Wnt protein in the form of a complex with afamin from a culture product. The method enables a Wnt protein having high Wnt activity to be produced in a simple and brief manner without use of special equipment.

公开(公告)号：US20250136674A1

公开(公告)日：2025-05-01

申请号：US18835365

申请日：2022-02-03

Applicant: Kyoto University ,  University of Fukui ,  Aichi Prefecture ,  Osaka University

Inventor： Katsu TAKAHASHI ,  Manabu SUGAI ,  Yoshihito TOKITA ,  Junichi TAKAGI ,  Emiko MIHARA

IPC: C07K16/22 ,  A61K39/00 ,  A61P1/02

Abstract: Provided are: an antibody which specifically binds to and neutralizes USAG-1 or an antigen-binding fragment thereof; and a pharmaceutical composition containing the antibody or the antigen-binding fragment.

公开(公告)号：US20220204346A1

公开(公告)日：2022-06-30

申请号：US17441971

申请日：2020-03-27

Applicant: OSAKA UNIVERSITY

Inventor： Tsuyoshi INOUE ,  Haruyasu ASAHARA ,  Kei OHKUBO ,  Kenji IWASAKI ,  Naoyuki MIYAZAKI ,  Mika HIROSE ,  Atsushi NAKAGAWA ,  Junichi TAKAGI ,  Takefumi DOI ,  Hiroaki ADACHI

IPC: C01B32/156 ,  C01B32/05 ,  C01B32/168 ,  C01B32/194 ,  H01J37/20

Abstract: The present invention provides a method for producing a substance with a modified carbon allotrope surface that can suppress or prevent uneven distribution, uneven orientation, and the like of a structural analysis target substance in a structural analysis by cryo-electron microscopy. A method for producing a substance with a modified carbon allotrope surface of the present invention includes: the step of surface-treating by reacting a carbon allotrope surface with a halogen oxide radical, wherein the carbon allotrope surface is modified by the surface-treating.

公开(公告)号：US20200283533A1

公开(公告)日：2020-09-10

申请号：US16808451

申请日：2020-03-04

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  C12N5/10 ,  C12N15/09 ,  A61K39/00 ,  C07K19/00 ,  A61P35/00

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20190276561A1

公开(公告)日：2019-09-12

申请号：US16345639

申请日：2017-11-07

Applicant: FUJIFILM WAKO PURE CHEMICAL CORPORATION ,  OSAKA UNIVERSITY

Inventor： Junichi TAKAGI

IPC: C07K16/46 ,  C07K1/30

Abstract: An object of the present invention is to provide a fragment antibody which can be conveniently produced as one having antigen-binding activity, and which has a greater ability to crystallize itself alone or as a complex with an antigen molecule than that of Fv-clasp (v1) even in a case where the fragment antibody is obtained in an E. coli expression system. The present invention relates to a fragment antibody including a complex of a peptide (VH(112C)-SARAH) in which an N-terminus of a SARAH domain is linked to a C-terminus of a heavy chain domain (VH region) of an antibody, and an amino acid residue of antibody residue 112 according to Chothia numbering scheme in the VH region is mutated to cysteine; and a peptide (VL-SARAH(37C)) in which an N-terminus of a SARAH domain is linked to a C-terminus of a light chain domain (VL region) of an antibody, and an amino acid residue at position 13 from the C-terminus in the SARAH domain is mutated to cysteine.

公开(公告)号：US20180230216A1

公开(公告)日：2018-08-16

申请号：US15751574

申请日：2016-08-02

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N15/09 ,  C12N5/10

CPC classification number: C07K16/2839 ,  A61K35/17 ,  A61K39/0011 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/10 ,  C12N15/09

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20170355953A1

公开(公告)日：2017-12-14

申请号：US15539241

申请日：2015-12-24

Applicant: OSAKA UNIVERSITY

Inventor： Junichi TAKAGI ,  Emiko MIHARA ,  Akira KIKUCHI

IPC: C12N5/00 ,  C12P21/02 ,  C12N15/09 ,  C07K14/00 ,  A61K38/00 ,  C07K19/00

Abstract: Provided is a novel method for producing a Wnt protein, which method comprises (1) a step of performing affinity purification targeting afamin to obtain a Wnt protein from a culture product, and/or (2) a step of performing affinity purification to obtain a Wnt protein in the form of a complex with afamin from a culture product. The method enables a Wnt protein having high Wnt activity to be produced in a simple and brief manner without use of special equipment.